Faricimab for chronic central serous chorioretinopathy
Treatments studied
Part of Eyes & vision clinical trials.
This study tests a medicine called faricimab, which is given as an eye injection, to see if it helps people with a chronic eye condition that causes fluid buildup under the retina. The trial compares faricimab to a sham (fake) treatment to see if it improves vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 21 years or older.
- You have had fluid under the retina for at least 3 months (chronic CSCR) with or without abnormal blood vessels.
- Your vision in the study eye is between roughly 20/32 and 20/300.
- You have not had certain eye treatments recently, like anti-VEGF injections in the past 6 months, photodynamic therapy, or corticosteroid injections into the eye.
- You have not had eye surgery in the past 3 months.
- If you are able to become pregnant, you must have a negative pregnancy test and use reliable birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses special eye scans to look at the back of the eye in people with central serous chorioretinopathy (a condition where fluid builds up under the retina). It aims to understand the condition better and may help guide future treatments.
This study tests a medication called faricimab, given as eye injections over a long period, for people with a specific type of wet age-related macular degeneration. The goal is to see if this treatment can help maintain or improve vision over time.
This study looks at the link between gut bacteria and central serous chorioretinopathy (CSC), a condition where fluid builds up under the retina. It may help us understand why some people get CSC and find better ways to treat it.
This study tests a personalized treatment plan using an investigational drug called faricimab for people who have a specific type of wet age-related macular degeneration known as polypoidal choroidal vasculopathy. The goal is to see if adjusting the time between injections based on your individual needs can safely dry up fluid in the retina and improve vision.
This trial tests a drug called faricimab (brand name Vabysmo) for treating abnormal blood vessel growth in the back of the eye, caused by a past infection with histoplasmosis. The goal is to see if it helps improve vision over 52 weeks.
This study tests a drug called faricimab (an injection into the eye) for treating diabetic macular edema, a condition where fluid builds up in the retina and causes vision loss. It is specifically for people of South Asian origin and aims to see how well and how long the treatment works and if it is safe.
Hear when a new Central Serous Chorioretinopathy (CSC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.